desvenlafaxine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4380 93413-62-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desvenlafaxine
  • desvenlafaxine succinate
  • pristiq
  • DVS-233
  • desvenlafaxine fumarate
The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
  • Molecular weight: 263.38
  • Formula: C16H25NO2
  • CLOGP: 2.68
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 43.70
  • ALOGS: -2.27
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 572 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 45 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.42 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 29, 2008 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product residue present 752.66 15.15 197 21967 3475 50579485
Drug withdrawal syndrome 632.85 15.15 278 21886 24803 50558157
Suicidal ideation 342.30 15.15 243 21921 55142 50527818
Withdrawal syndrome 288.70 15.15 145 22019 17445 50565515
Feeling abnormal 275.77 15.15 306 21858 125186 50457774
Crying 268.33 15.15 145 22019 20271 50562689
Anxiety 231.97 15.15 334 21830 177272 50405688
Insomnia 218.39 15.15 322 21842 174543 50408417
Irritability 197.18 15.15 134 22030 28292 50554668
Dizziness 167.27 15.15 426 21738 345943 50237017
Anger 133.73 15.15 75 22089 11258 50571702
Nausea 130.22 15.15 630 21534 704768 49878192
Hyperhidrosis 113.26 15.15 166 21998 89260 50493700
Headache 109.94 15.15 475 21689 506060 50076900
Condition aggravated 98.92 15.15 320 21844 296738 50286222
Panic attack 94.95 15.15 74 22090 19268 50563692
Nervousness 92.86 15.15 85 22079 27566 50555394
Agitation 90.17 15.15 114 22050 53270 50529690
Depression 88.51 15.15 212 21952 165211 50417749
Tremor 87.59 15.15 170 21994 114733 50468227
Emotional disorder 87.31 15.15 58 22106 11778 50571182
Abnormal dreams 84.16 15.15 52 22112 9325 50573635
Intentional product misuse 84.05 15.15 103 22061 46631 50536329
Feeling jittery 73.54 15.15 51 22113 11109 50571851
Suicide attempt 63.95 15.15 95 22069 51637 50531323
Nightmare 63.07 15.15 54 22110 16032 50566928
Completed suicide 62.04 15.15 161 22003 131728 50451232
Thinking abnormal 61.35 15.15 43 22121 9524 50573436
Persistent genital arousal disorder 58.80 15.15 15 22149 237 50582723
Serotonin syndrome 51.93 15.15 59 22105 24654 50558306
Disturbance in attention 50.12 15.15 65 22099 31121 50551839
Overdose 49.21 15.15 124 22040 99603 50483357
Middle insomnia 48.77 15.15 38 22126 9883 50573077
Migraine 47.41 15.15 103 22061 75177 50507783
Paraesthesia 46.80 15.15 137 22027 120106 50462854
Seizure 43.69 15.15 132 22032 117742 50465218
Drug ineffective 43.68 15.15 548 21616 818785 49764175
Depressed mood 42.78 15.15 63 22101 33960 50549000
Vision blurred 42.20 15.15 101 22063 78546 50504414
Acute kidney injury 41.79 15.15 24 22140 228034 50354926
Anaemia 41.58 15.15 30 22134 252426 50330534
Pyrexia 41.56 15.15 64 22100 380139 50202821
Mania 41.48 15.15 36 22128 10880 50572080
Drug screen positive 41.45 15.15 23 22141 3379 50579581
Tinnitus 41.15 15.15 56 22108 28076 50554884
Mydriasis 40.29 15.15 35 22129 10592 50572368
Synovitis 39.88 15.15 4 22160 123861 50459099
Anorgasmia 38.98 15.15 13 22151 542 50582418
Death 38.27 15.15 52 22112 325327 50257633
Energy increased 38.20 15.15 19 22145 2233 50580727
Impaired driving ability 38.19 15.15 23 22141 3938 50579022
Product substitution issue 37.34 15.15 38 22126 14019 50568941
Coma scale abnormal 36.69 15.15 24 22140 4747 50578213
Neutropenia 36.19 15.15 10 22154 147955 50435005
Joint swelling 35.61 15.15 33 22131 245253 50337707
Somnolence 35.39 15.15 148 22016 154837 50428123
Maternal exposure during pregnancy 35.17 15.15 13 22151 159765 50423195
Blood pressure increased 35.11 15.15 133 22031 132999 50449961
Mood altered 34.79 15.15 35 22129 12738 50570222
Treatment failure 34.23 15.15 9 22155 137628 50445332
Drug screen false positive 34.04 15.15 13 22151 806 50582154
Aggression 33.90 15.15 44 22120 21072 50561888
Systemic lupus erythematosus 33.47 15.15 10 22154 140612 50442348
Pre-existing condition improved 32.34 15.15 26 22138 7071 50575889
Therapeutic response unexpected 31.75 15.15 37 22127 15878 50567082
Weight increased 31.70 15.15 173 21991 201718 50381242
Stomatitis 30.80 15.15 4 22160 101340 50481620
Restlessness 30.76 15.15 46 22118 25127 50557833
Peripheral swelling 30.72 15.15 27 22137 205909 50377051
Thrombocytopenia 30.53 15.15 9 22155 127664 50455296
Drug hypersensitivity 30.41 15.15 201 21963 250809 50332151
Bruxism 30.21 15.15 18 22146 3022 50579938
Infusion related reaction 29.43 15.15 19 22145 169538 50413422
Paranoia 29.37 15.15 29 22135 10319 50572641
General physical health deterioration 29.05 15.15 13 22151 142421 50440539
Mood swings 28.40 15.15 35 22129 15919 50567041
Palpitations 27.93 15.15 98 22066 94408 50488552
Nonspecific reaction 27.22 15.15 14 22150 1765 50581195
Rheumatoid arthritis 26.27 15.15 30 22134 202520 50380440
Libido decreased 26.07 15.15 15 22149 2361 50580599
Sepsis 25.77 15.15 13 22151 132912 50450048
Amnesia 25.66 15.15 57 22107 42203 50540757
Tachyphrenia 25.65 15.15 12 22152 1233 50581727
Abnormal behaviour 25.58 15.15 37 22127 19621 50563339
Euphoric mood 25.47 15.15 18 22146 4037 50578923
Mental disorder 25.19 15.15 39 22125 21952 50561008
Hostility 24.35 15.15 13 22151 1769 50581191
Infection 24.23 15.15 24 22140 172930 50410030
Pericarditis 24.16 15.15 3 22161 78686 50504274
Lower respiratory tract infection 24.09 15.15 6 22158 95195 50487765
Dissociation 23.91 15.15 14 22150 2277 50580683
Hypersensitivity vasculitis 23.33 15.15 17 22147 3998 50578962
Loss of libido 22.78 15.15 11 22153 1212 50581748
Panic reaction 22.78 15.15 16 22148 3553 50579407
Stress 22.56 15.15 63 22101 53730 50529230
Unevaluable event 22.40 15.15 57 22107 46009 50536951
Post-traumatic stress disorder 22.28 15.15 17 22147 4286 50578674
Prescribed overdose 21.25 15.15 29 22135 14571 50568389
Bipolar disorder 21.18 15.15 20 22144 6737 50576223
Apathy 21.14 15.15 21 22143 7527 50575433
Pneumonia 20.30 15.15 91 22073 378310 50204650
Muscle twitching 20.01 15.15 29 22135 15402 50567558
Hallucination 19.92 15.15 55 22109 46602 50536358
Negative thoughts 19.88 15.15 9 22155 857 50582103
Swelling 19.87 15.15 36 22128 200836 50382124
Arthropathy 19.81 15.15 24 22140 157882 50425078
Febrile neutropenia 19.77 15.15 9 22155 97658 50485302
Brain injury 19.23 15.15 18 22146 5996 50576964
Dyspnoea 19.15 15.15 151 22013 547457 50035503
Suicidal behaviour 18.58 15.15 12 22152 2322 50580638
Wrong technique in product usage process 18.54 15.15 60 22104 55450 50527510
Memory impairment 18.25 15.15 76 22088 79284 50503676
Tardive dyskinesia 18.11 15.15 19 22145 7260 50575700
Tearfulness 17.86 15.15 14 22150 3673 50579287
Intestinal pseudo-obstruction 17.83 15.15 8 22156 746 50582214
Change in seizure presentation 17.55 15.15 6 22158 270 50582690
Malaise 17.51 15.15 224 21940 335308 50247652
Haemoglobin decreased 17.41 15.15 18 22146 127198 50455762
Renal impairment 16.90 15.15 6 22158 75655 50507305
Hallucination, auditory 16.67 15.15 22 22142 10706 50572254
Urinary tract infection 16.58 15.15 47 22117 223973 50358987
Dry mouth 16.37 15.15 58 22106 56120 50526840
Yawning 16.21 15.15 8 22156 925 50582035
Impatience 16.09 15.15 6 22158 348 50582612
Decreased interest 15.95 15.15 12 22152 2964 50579996
Feeling drunk 15.84 15.15 13 22151 3640 50579320
Blood triglycerides increased 15.76 15.15 22 22142 11290 50571670
Galactorrhoea 15.62 15.15 13 22151 3710 50579250
Wound 15.60 15.15 14 22150 105780 50477180
Coma 15.57 15.15 3 22161 56876 50526084
Wernicke-Korsakoff syndrome 15.46 15.15 4 22160 67 50582893
Impaired work ability 15.36 15.15 24 22140 13616 50569344
Drug effective for unapproved indication 15.19 15.15 10 22154 1999 50580961

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product residue present 225.41 22.80 60 6027 2479 29565961
Drug withdrawal syndrome 170.05 22.80 80 6007 17904 29550536
Serotonin syndrome 141.61 22.80 70 6017 17442 29550998
Suicidal ideation 118.41 22.80 79 6008 34637 29533803
Anxiety 90.28 22.80 99 5988 85266 29483174
Hyperhidrosis 73.70 22.80 78 6009 64462 29503978
Suicide attempt 65.43 22.80 55 6032 34055 29534385
Overdose 61.82 22.80 79 6008 79740 29488700
Sexual dysfunction 58.39 22.80 27 6060 5787 29562653
Withdrawal syndrome 52.48 22.80 31 6056 10961 29557479
Insomnia 50.89 22.80 76 6011 88685 29479755
Feeling abnormal 50.40 22.80 59 6028 54386 29514054
Anger 50.13 22.80 30 6057 10860 29557580
Major depression 45.47 22.80 20 6067 3815 29564625
Drug ineffective 45.19 22.80 170 5917 363000 29205440
Thinking abnormal 39.53 22.80 20 6067 5216 29563224
Completed suicide 39.02 22.80 68 6019 90178 29478262
Erectile dysfunction 36.50 22.80 30 6057 17979 29550461
Schizophreniform disorder 35.65 22.80 7 6080 70 29568370
Coma scale abnormal 34.49 22.80 16 6071 3453 29564987
Nervousness 34.37 22.80 24 6063 11282 29557158
Dry mouth 33.48 22.80 31 6056 21753 29546687
Depression 30.29 22.80 59 6028 85088 29483352
Mania 30.16 22.80 20 6067 8643 29559797
Headache 29.93 22.80 91 5996 173916 29394524
Libido decreased 28.36 22.80 15 6072 4283 29564157
Tremor 27.43 22.80 52 6035 73486 29494954
Drug screen positive 27.18 22.80 14 6073 3787 29564653
Abnormal behaviour 26.42 22.80 28 6059 23099 29545341
Irritability 25.63 22.80 27 6060 22125 29546315
Paralysis 24.92 22.80 15 6072 5482 29562958
Acute kidney injury 24.57 22.80 12 6075 265255 29303185
Drug screen false positive 24.51 22.80 8 6079 672 29567768
Dizziness 24.43 22.80 90 5997 189594 29378846
Paraesthesia 23.79 22.80 41 6046 53804 29514636
Emotional disorder 23.77 22.80 14 6073 4917 29563523
Intentional product misuse 23.21 22.80 32 6055 34629 29533811
Bipolar disorder 23.17 22.80 12 6075 3283 29565157

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Withdrawal syndrome 278.99 15.26 135 18060 23357 64457180
Drug withdrawal syndrome 234.30 15.26 132 18063 31159 64449378
Suicidal ideation 219.58 15.26 168 18027 66374 64414163
Feeling abnormal 208.52 15.26 221 17974 133381 64347156
Product residue present 183.69 15.26 58 18137 3184 64477353
Anxiety 175.58 15.26 249 17946 202400 64278137
Crying 164.72 15.26 90 18105 20000 64460537
Serotonin syndrome 140.19 15.26 104 18091 39178 64441359
Irritability 126.02 15.26 95 18100 36651 64443886
Overdose 115.00 15.26 180 18015 159386 64321151
Anger 103.36 15.26 61 18134 15680 64464857
Insomnia 100.31 15.26 191 18004 197645 64282892
Suicide attempt 99.32 15.26 111 18084 70896 64409641
Dizziness 86.56 15.26 292 17903 429871 64050666
Completed suicide 85.91 15.26 193 18002 224221 64256316
Hyperhidrosis 81.83 15.26 135 18060 124785 64355752
Emotional disorder 77.93 15.26 47 18148 12560 64467977
Depression 75.05 15.26 162 18033 183129 64297408
Coma scale abnormal 69.78 15.26 37 18158 7737 64472800
Headache 67.93 15.26 312 17883 529155 63951382
Persistent genital arousal disorder 65.78 15.26 15 18180 230 64480307
Drug ineffective 64.18 15.26 430 17765 839817 63640720
Nausea 62.31 15.26 406 17789 785394 63695143
Drug hypersensitivity 62.14 15.26 177 18018 237638 64242899
Tremor 61.78 15.26 132 18063 148098 64332439
Nervousness 59.06 15.26 56 18139 29500 64451037
Intentional product misuse 56.84 15.26 85 18110 72210 64408327
Panic attack 56.41 15.26 47 18148 20906 64459631
Acute kidney injury 55.23 15.26 29 18166 449211 64031326
Depressed mood 52.05 15.26 61 18134 40951 64439586
Thinking abnormal 51.37 15.26 35 18160 11521 64469016
Product substitution issue 47.94 15.26 40 18155 17821 64462716
Abnormal dreams 47.54 15.26 32 18163 10324 64470213
Nightmare 46.24 15.26 42 18153 20951 64459586
Major depression 40.37 15.26 26 18169 7790 64472747
Agitation 38.29 15.26 80 18115 88287 64392250
Migraine 36.07 15.26 64 18131 62613 64417924
Feeling jittery 35.34 15.26 27 18168 10608 64469929
Condition aggravated 33.42 15.26 199 17996 372227 64108310
Neutropenia 33.25 15.26 13 18182 239611 64240926
Impaired driving ability 33.09 15.26 19 18176 4635 64475902
Anaemia 32.91 15.26 35 18160 378645 64101892
Tinnitus 32.52 15.26 44 18151 34089 64446448
Mood altered 31.39 15.26 30 18165 15949 64464588
Mental disorder 31.35 15.26 38 18157 26407 64454130
Thrombocytopenia 31.28 15.26 12 18183 223789 64256748
Mania 30.90 15.26 30 18165 16256 64464281
Paranoia 30.80 15.26 30 18165 16322 64464215
Pre-existing condition improved 30.07 15.26 18 18177 4744 64475793
Febrile neutropenia 29.88 15.26 8 18187 187649 64292888
Seizure 29.69 15.26 109 18086 166783 64313754
Disturbance in attention 29.04 15.26 46 18149 41028 64439509
Prescribed overdose 28.77 15.26 32 18163 20299 64460238
Abnormal behaviour 28.53 15.26 41 18154 33581 64446956
General physical health deterioration 28.50 15.26 11 18184 204414 64276123
Schizophreniform disorder 28.40 15.26 7 18188 152 64480385
Sepsis 28.06 15.26 15 18180 230326 64250211
Panic reaction 27.46 15.26 16 18179 4011 64476526
Hostility 27.13 15.26 13 18182 2194 64478343
Pyrexia 26.35 15.26 76 18119 558568 63921969
Mood swings 25.59 15.26 28 18167 17440 64463097
Therapeutic response unexpected 24.47 15.26 27 18168 16974 64463563
Suicidal behaviour 23.83 15.26 13 18182 2874 64477663
Reversible cerebral vasoconstriction syndrome 23.46 15.26 12 18183 2330 64478207
Paraesthesia 22.37 15.26 86 18109 134436 64346101
Bipolar disorder 22.10 15.26 17 18178 6744 64473793
Hypersensitivity vasculitis 22.10 15.26 17 18178 6744 64473793
Affect lability 21.81 15.26 19 18176 8971 64471566
Tardive dyskinesia 21.47 15.26 19 18176 9159 64471378
Frustration tolerance decreased 21.35 15.26 16 18179 6109 64474428
Renal impairment 21.03 15.26 6 18189 135011 64345526
Stress 20.82 15.26 50 18145 60484 64420053
Dissociation 20.63 15.26 12 18183 2999 64477538
Renal failure 20.46 15.26 13 18182 181675 64298862
Drug dependence 20.44 15.26 35 18160 33277 64447260
Amnesia 20.09 15.26 43 18152 48226 64432311
Palpitations 20.07 15.26 70 18125 104418 64376119
Drug screen positive 20.04 15.26 15 18180 5714 64474823
Self-injurious ideation 19.96 15.26 12 18183 3185 64477352
Road traffic accident 19.79 15.26 33 18162 30712 64449825
Memory impairment 19.68 15.26 61 18134 85621 64394916
Hypersomnia 19.67 15.26 26 18169 19691 64460846
Malaise 19.63 15.26 184 18011 396063 64084474
Malignant neoplasm progression 19.56 15.26 4 18191 112867 64367670
Change in seizure presentation 19.52 15.26 6 18189 301 64480236
Dyspnoea 19.47 15.26 121 18074 718553 63761984
Energy increased 18.92 15.26 11 18184 2747 64477790
Bradycardia 18.88 15.26 5 18190 118214 64362323
Multiple organ dysfunction syndrome 18.86 15.26 3 18192 101410 64379127
Product dose omission issue 18.68 15.26 106 18089 194641 64285896
Mental impairment 18.59 15.26 23 18172 16320 64464217
Bruxism 18.58 15.26 12 18183 3612 64476925
Drug effective for unapproved indication 18.33 15.26 12 18183 3696 64476841
Contraindicated product administered 18.32 15.26 4 18191 107825 64372712
Impaired work ability 18.25 15.26 22 18173 15197 64465340
Death 17.77 15.26 73 18122 482632 63997905
Dry mouth 17.74 15.26 47 18148 60371 64420166
Septic shock 17.74 15.26 4 18191 105433 64375104
Muscle twitching 17.35 15.26 24 18171 18974 64461563
Somnolence 17.06 15.26 107 18088 203538 64276999
Wernicke-Korsakoff syndrome 17.04 15.26 4 18191 70 64480467
Ankyloglossia congenital 16.70 15.26 3 18192 12 64480525
Intestinal pseudo-obstruction 16.49 15.26 9 18186 1991 64478546
Brain injury 16.41 15.26 17 18178 9948 64470589
Synovitis 16.19 15.26 4 18191 99086 64381451
Anorgasmia 16.12 15.26 7 18188 942 64479595
Illness 16.10 15.26 25 18170 21913 64458624
Vision blurred 16.05 15.26 59 18136 90257 64390280
Paralysis 15.97 15.26 18 18177 11577 64468960
Insulinoma 15.89 15.26 4 18191 95 64480442
Therapeutic response changed 15.87 15.26 7 18188 977 64479560
Hypotension 15.70 15.26 55 18140 380919 64099618
Aggression 15.70 15.26 38 18157 46194 64434343
Vertigo 15.43 15.26 44 18151 58967 64421570

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX23 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D000068760 Serotonin and Noradrenaline Reuptake Inhibitors
FDA EPC N0000175749 Serotonin and Norepinephrine Reuptake Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:83399 marine xenobiotic metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Generalized anxiety disorder off-label use 21897009 DOID:14320
Social phobia off-label use 25501002 DOID:11257
Menopausal flushing off-label use 198436008
Neuropathic pain off-label use 247398009
Panic disorder off-label use 371631005 DOID:594
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Cerebrovascular disease contraindication 62914000 DOID:6713
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Impaired renal function disorder contraindication 197663003
Mania contraindication 231494001
Hypomania contraindication 231496004
Interstitial lung disease contraindication 233703007 DOID:3082
Disease of liver contraindication 235856003 DOID:409
Hypertriglyceridemia contraindication 302870006
Serotonin syndrome contraindication 371089000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.79 acidic
pKa2 9.33 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE PRISTIQ PF PRISM CV N021992 Feb. 29, 2008 RX TABLET, EXTENDED RELEASE ORAL 6673838 March 1, 2022 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 100MG BASE PRISTIQ PF PRISM CV N021992 Feb. 29, 2008 RX TABLET, EXTENDED RELEASE ORAL 6673838 March 1, 2022 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 25MG BASE PRISTIQ PF PRISM CV N021992 Aug. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 6673838 March 1, 2022 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 25MG BASE PRISTIQ PF PRISM CV N021992 Aug. 20, 2014 RX TABLET, EXTENDED RELEASE ORAL 6673838 March 1, 2022 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 50MG BASE PRISTIQ PF PRISM CV N021992 Feb. 29, 2008 RX TABLET, EXTENDED RELEASE ORAL 6673838 March 1, 2022 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 50MG BASE PRISTIQ PF PRISM CV N021992 Feb. 29, 2008 RX TABLET, EXTENDED RELEASE ORAL 6673838 March 1, 2022 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.33 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 6.28 WOMBAT-PK CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 7.22 CHEMBL

External reference:

IDSource
D07793 KEGG_DRUG
4027338 VUID
N0000176142 NUI
386750-22-7 SECONDARY_CAS_RN
93414-04-1 SECONDARY_CAS_RN
4027338 VANDF
C1880288 UMLSCUI
CHEBI:83527 CHEBI
CHEMBL1118 ChEMBL_ID
CHEMBL1201728 ChEMBL_ID
DB06700 DRUGBANK_ID
7158 IUPHAR_LIGAND_ID
8361 INN_ID
NG99554ANW UNII
125017 PUBCHEM_CID
683693 RXNORM
132507 MMSL
200628 MMSL
25184 MMSL
339716 MMSL
38906 MMSL
d07113 MMSL
012574 NDDF
012575 NDDF
015249 NDDF
430267008 SNOMEDCT_US
430271006 SNOMEDCT_US
433292007 SNOMEDCT_US
D000069468 MESH_DESCRIPTOR_UI
CHEMBL3989861 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1210 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1211 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 31 sections
Pristiq Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 0008-1222 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 31 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0400 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0401 TABLET, FILM COATED, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0603 TABLET, FILM COATED, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3659 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3659 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3660 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3660 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4060 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4060 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 35208-009 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 35208-010 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
PristiqExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 43063-262 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 31 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-152 TABLET, EXTENDED RELEASE 50 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-153 TABLET, EXTENDED RELEASE 100 mg ORAL NDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-540 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-541 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 46708-542 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Succinate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4069 TABLET, EXTENDED RELEASE 50 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4388 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4806 TABLET, FILM COATED, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 50090-5274 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine Human Prescription Drug Label 1 50090-5293 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 51407-021 TABLET, EXTENDED RELEASE 25 mg ORAL ANDA 30 sections
Desvenlafaxine HUMAN PRESCRIPTION DRUG LABEL 1 51407-022 TABLET, EXTENDED RELEASE 50 mg ORAL ANDA 30 sections